NO20013966L - Kombinasjoner for behandling av sykdommer som involverer angiogenese - Google Patents

Kombinasjoner for behandling av sykdommer som involverer angiogenese

Info

Publication number
NO20013966L
NO20013966L NO20013966A NO20013966A NO20013966L NO 20013966 L NO20013966 L NO 20013966L NO 20013966 A NO20013966 A NO 20013966A NO 20013966 A NO20013966 A NO 20013966A NO 20013966 L NO20013966 L NO 20013966L
Authority
NO
Norway
Prior art keywords
combinations
treatment
diseases involving
involving angiogenesis
formation
Prior art date
Application number
NO20013966A
Other languages
English (en)
Other versions
NO20013966D0 (no
Inventor
Peter David Davis
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Publication of NO20013966D0 publication Critical patent/NO20013966D0/no
Publication of NO20013966L publication Critical patent/NO20013966L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
NO20013966A 1999-02-16 2001-08-15 Kombinasjoner for behandling av sykdommer som involverer angiogenese NO20013966L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903404.3A GB9903404D0 (en) 1999-02-16 1999-02-16 Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
PCT/GB2000/000511 WO2000048591A1 (en) 1999-02-16 2000-02-15 Combinations for the treatment of diseases involving angiogenesis

Publications (2)

Publication Number Publication Date
NO20013966D0 NO20013966D0 (no) 2001-08-15
NO20013966L true NO20013966L (no) 2001-10-15

Family

ID=10847791

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013966A NO20013966L (no) 1999-02-16 2001-08-15 Kombinasjoner for behandling av sykdommer som involverer angiogenese

Country Status (21)

Country Link
US (2) US7087627B1 (no)
EP (1) EP1161235B1 (no)
JP (1) JP4708569B2 (no)
KR (2) KR20010102038A (no)
CN (1) CN1344159B (no)
AT (1) ATE288264T1 (no)
AU (1) AU775242B2 (no)
BR (1) BR0008254A (no)
CA (1) CA2362281C (no)
DE (1) DE60017878T2 (no)
DK (1) DK1161235T3 (no)
ES (1) ES2237407T3 (no)
GB (1) GB9903404D0 (no)
HK (1) HK1040919B (no)
IL (2) IL144847A0 (no)
MX (1) MXPA01008245A (no)
NO (1) NO20013966L (no)
NZ (1) NZ513429A (no)
PT (1) PT1161235E (no)
WO (1) WO2000048591A1 (no)
ZA (1) ZA200106688B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
EP1311262A4 (en) 2000-07-28 2005-06-01 Cancer Rec Tech Ltd COMBINED TREATMENT AGAINST CANCER
US20050153939A1 (en) 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
YU29803A (sh) * 2000-10-27 2006-05-25 Aventis Pharma S.A. Kombinacija kamptotekina i derivata stilbena za lečenje raka
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
AU2008202468B2 (en) * 2001-07-13 2011-08-11 Oxigene, Inc. Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
CA2453442C (en) * 2001-07-13 2011-02-01 Oxigene, Inc. Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EP1287854B1 (en) * 2001-08-30 2005-11-30 Cancer Research Technology Limited Anti-cancer combinations of DMXAA and paclitaxel or docetaxel
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
PT2219451E (pt) 2007-11-21 2015-02-09 Oxigene Inc Processo para o tratamento de neoplasmas hematopoiéticos
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107771A0 (en) 1992-11-27 1994-02-27 Wellcome Found Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5424447A (en) 1993-07-07 1995-06-13 The Medical College Of Wisconsin Research Foundation, Inc. Heme binding compounds and use thereof
GB9320484D0 (en) * 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
WO1996018617A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
AU2213197A (en) 1996-03-05 1997-09-22 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

Also Published As

Publication number Publication date
ATE288264T1 (de) 2005-02-15
JP2002537251A (ja) 2002-11-05
KR20010102038A (ko) 2001-11-15
CN1344159B (zh) 2011-09-28
KR20070034642A (ko) 2007-03-28
ZA200106688B (en) 2002-08-14
DE60017878T2 (de) 2006-01-26
AU775242B2 (en) 2004-07-22
EP1161235B1 (en) 2005-02-02
PT1161235E (pt) 2005-05-31
HK1040919B (zh) 2005-05-13
DK1161235T3 (da) 2005-05-09
IL144847A (en) 2006-10-31
ES2237407T3 (es) 2005-08-01
NO20013966D0 (no) 2001-08-15
US20060198846A1 (en) 2006-09-07
MXPA01008245A (es) 2002-10-23
BR0008254A (pt) 2001-11-06
CN1344159A (zh) 2002-04-10
HK1040919A1 (en) 2002-06-28
GB9903404D0 (en) 1999-04-07
CA2362281A1 (en) 2000-08-24
JP4708569B2 (ja) 2011-06-22
IL144847A0 (en) 2002-06-30
CA2362281C (en) 2008-11-18
EP1161235A1 (en) 2001-12-12
NZ513429A (en) 2003-10-31
WO2000048591A1 (en) 2000-08-24
AU2559000A (en) 2000-09-04
DE60017878D1 (de) 2005-03-10
US7087627B1 (en) 2006-08-08

Similar Documents

Publication Publication Date Title
NO20013966L (no) Kombinasjoner for behandling av sykdommer som involverer angiogenese
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
SE0101932D0 (sv) Pharmaceutical combinations
HRP20050439B1 (en) New use of dextran sulfate
AU2002213421A1 (en) Condensed pyridoindole derivatives
AU2001266575A1 (en) Chemical compounds
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
DK0912185T3 (da) Nye farmaceutiske sammensætninger indeholdende steroidnitratesterderivater, der kan anvendes som antiinflammatoriske lægemidler
PL351710A1 (en) Anti−inflammatory therapy for inflammatory mediated infection
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
WO2000040583A3 (de) Imidazo[4,5-c]-pyridin-4-on-derivate
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
BR9813719A (pt) Agentes terapêuticos
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
NZ516620A (en) 1,4-substituted 4,4-diaryl cyclohexanes
DE60121048D1 (de) PYRAZINOi1&#39;2&#39;:1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR199700735T1 (xx) �ste�e g�re azt,DD1 ya da DDC ile birlikte ters transkritaz inhibit�r� 3T ve HIV proteaz inhibit�r� indinavirin kullan�lmas�yla HIV enfeksiyoun i�in bir arada terapi.